Sofosbuvir

Daklinza used in combination with sofosbuvir (with or without ribavirin)was shown to be effective at clearing the hepatitis C virus from the blood in a main study involving 211 adults. The patients in the study were infected with genotypes 1, 2 or 3 andall received treatment for 12 or 24 weeks. Most patients had not previously been treated for hepatitis C, though some had genotype 1 infection that was resistant to standard medicines (consisting of either telaprevir or boceprevir–the socalled NS34A inhibitors in combination with peginterferon alfa and ribavirin).Around 99% of patients with genotype 1 infection (125 out of 126), 96% of patients with genotype 2 infection (25 out of 26) and 89% of patients with genotype 3 infection (16 out of 18) did not show any sign of the virus in their blood 12 weeks after the end of their planned treatment. Additional studies involving patients with genotypes 4 indicate that Daklinza is also as effective against genotype 4 as it is against genotype 1